Telix Pharma Partners With Curium Pharma For Commercialing Scintimun®

Telix has signed a licensing and supplies agreement with Curium Pharma for marketing and distribution control of Scintimun® (99mTc-besilesomab, otherwise known as TLX66-CDx), which is a diagnostic radiopharmaceutical for infection imaging. Under the deal, Curium will remain an important strategic contract manufacturer of Scintimun. Scintimun is an internationally approved product that was previously manufactured and commercialized by Curium Pharma through an out-license from Telix via the acquisition of TheraPharm in 2020. 

“We are pleased to be bringing Scintimun back to Telix and see it as a valuable addition to our portfolio. In the near term, the plan will increase sales for its current indication by improving product availability, pricing and commercial consistency. There is significant potential to expand clinical utility, including as a “companion imaging” tool for Telix’s TLX66 bone marrow conditioning candidate. We look forward to leveraging its potential for expanded clinical indications in serious diseases that represent an unmet medical need,” commented Kevin Richardson, Chief Executive Officer of Telix Precision Medicine.

Subsequent to a strategic evaluation, Telix has concluded that Scintimun's sales and marketing should be in-house. This step is intended to broaden the product’s business sales and usage in further therapeutic applications. Telix also intends to expand the use of Scintimun to support patient identification and safety for TLX66 (90Y-besilesomab), a therapeutic candidate designed for bone marrow conditioning in hematopoietic stem cell transplantation (HSCT). 

Ciril Faia, Chief Executive Officer of Curium Pharma Europe, said in a statement, “This agreement is a milestone for our Saclay site, as it recognizes our capabilities and expertise as a contract manufacturing organization in the field of nuclear medicine. It underscores the trust placed in our teams and the quality of their work. We are pleased that Scintimun will continue to benefit thousands of patients worldwide, and we are proud to support Telix in maximizing the potential of this impactful diagnostic tool.”